Ignite Creation Date:
2024-05-05 @ 9:55 PM
Last Modification Date:
2024-10-26 @ 10:11 AM
Study NCT ID:
NCT00987948
Status:
COMPLETED
Last Update Posted:
2017-03-22
First Post:
2009-09-29
Brief Title:
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
Sponsor:
University of Hawaii
Organization:
University of Hawaii
Study Overview
Official Title:
Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
High levels of HIV infection within blood monocytemacrophages a type of white cells in the bloodstream increases risk of dementia in HIV-infected individuals Maraviroc Selzentry is a HIV medication that works by blocking the entry of HIV in cells including monocytesmacrophages that use a receptor called CCR5 The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocytemacrophages will lead to a decrease in the levels of infected monocytemacrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy MRS a form of MRI study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None